US20130331321A1 - Perhexiline for treating chronic heart failure - Google Patents

Perhexiline for treating chronic heart failure Download PDF

Info

Publication number
US20130331321A1
US20130331321A1 US13/841,635 US201313841635A US2013331321A1 US 20130331321 A1 US20130331321 A1 US 20130331321A1 US 201313841635 A US201313841635 A US 201313841635A US 2013331321 A1 US2013331321 A1 US 2013331321A1
Authority
US
United States
Prior art keywords
heart failure
perhexiline
mammal
chronic heart
symptomatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/841,635
Inventor
Michael Paul Frenneaux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heart Metabolics Ltd
Original Assignee
Heart Metabolics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heart Metabolics Ltd filed Critical Heart Metabolics Ltd
Priority to US13/841,635 priority Critical patent/US20130331321A1/en
Publication of US20130331321A1 publication Critical patent/US20130331321A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • Chronic heart failure is associated with considerable morbidity and mortality despite recent advances in heart treatments.
  • CHF chronic heart failure
  • There are a number of aetiological conditions that ultimately result in chronic heart failure including coronary artery disease, different cardiomyopathies, hypertension, or valvular diseases.
  • a detailed characterization of chronic heart failure as a clinical syndrome may be found in Hunt S A, Baker D W, Chin M H, Cinquegrani M P, Feldman A M, Francis G S, Ganiats T G, Goldstein S, Gregoratos G, Jessup M L, Noble R J, Packer M, Silver M A, Stevenson L W.
  • Coronary artery disease (obstruction or blockage of the arteries of the heart) leads to ischaemia; this is characterized by a lack of blood supply to tissues; in this case the heart. This lack of this essential oxygen and nutrients can result in the tissue becoming impaired or permanently damaged. Once damaged the cardiac tissue is unable to perform its function. As such, the strength and efficiency of the heart muscle is reduced (this is technically termed left ventricular systolic dysfunction and results in a reduced ejection fraction; a measure of the pumping capacity of the heart). In addition to its ability to damage the heart muscle; cardiac ischaemia is frequently though not invariably identified by the physical symptom of angina (in some cases—ischaemia may occur without the correlate of anginal chest pain).
  • Angina typically occurs under circumstances that would be expected to increase the hearts workload; resulting in an increased requirement for energy. This increased energy requirement necessitates increased oxygen provision that cannot be provided in the presence of arterial blockage; causing relative ischaemia and hence pain.
  • Exercise is a good example of this, where the output of the heart is increased but the blood supply does not match this increase in performance and thus some of the heart tissue becomes ischaemic resulting in pain.
  • This ischaemia despite causing pain need not invariably result in irreversible heart damage and is not invariably related to pump dysfunction.
  • ischaemia can cause both angina and heart failure, the exact manifestation of ischaemia relates to its severity and time course. Ultimately ischaemia as an inciting influence for heart failure is dissociable from its capacity to cause angina; they may or may not co-exist.
  • cardiac arrhythmias abnormal heart electrical rhythms
  • hypertension high blood pressure
  • valve diseases infections, toxins or impairment in the nervous stimulation of the heart to name but a few.
  • heart failure may be viewed as a progressive disorder that is initiated after an index event either damages the heart muscle, with a resultant loss 15 of functioning cardiac myocytes, or alternatively disrupts the ability of the myocardium to generate force, thereby preventing the heart from contracting normally.
  • This index event may have an abrupt onset, as in the case of a myocardial infarction (heart attack), it may have a gradual or insidious onset, as in the case hemodynamic pressure or volume overloading, or it may be hereditary, as in the case of many of the genetic cardiomyopathies.
  • the feature that is common to all of these index events is that they all, in some manner, produce a decline in pumping capacity of the heart. Following the initial decline in pumping capacity of the heart, acutely, patients may become very symptomatic; they may be minimally symptomatic or may even remain asymptomatic. However, the decreased pump capacity generally results in a diminished cardiac output. This chronically activates the neurohumoral system, particularly the sympathetic nervous system, the renin-angiotensin-aldosterone system, and potentiates the release of vasopressin.
  • the common unified programme of the failing heart irrespective of the inciting insult thus includes chronic energy starvation. It has been postulated that these energy changes are not simply just a feature of CHF but are of mechanistic importance in chronic heart failure.
  • the failing heart is characterized by a marked change in substrate preference away from fatty acid metabolism toward glucose metabolism.
  • Glucose is a more efficient cellular fuel and this particular adaptation may therefore be an adaptive feature of chronic heart failure—partially mitigating the effect of energy deficit. It therefore follows that augmentation of “metabolic remodeling” is a potential target in chronic heart failure; however to date there has been a paucity of even animal data to confirm this assertion.
  • Perhexiline (2-(2,2-dicyclohexylethyl)piperidine) is a known anti-anginal agent that operates principally by virtue of its ability to shift metabolism in the heart from free fatty acid metabolism to glucose, which is more energy efficient. Aside from being used for the treatment of angina as a manifestation of ischaemia (in patients who may or may not coincidentally have heart failure), there is no record of using perhexiline to treat instances of non-ischaemia and certainly no known use of this drug to treat instances of heart failure independent of angina. Phrased alternatively; while perhexiline has been used to treat patients with angina and ischaemia at the point where this may be an inciting influence for heart failure as demonstrated by arrow (a) in FIG.
  • perhexiline may be useful in the modification of chronic metabolic remodelling in the distinct stereotyped phenotype of chronic heart failure as demonstrated by arrow (b) in FIG. 1 .
  • perhexiline has been used as an anti-ischaemic agent at juncture a, the inciting phase; although even at this stage it has not been used explicitly as an antifailure agent.
  • the present invention postulates that metabolic manipulation with perhexiline is effective in modifying not an inciting influence; but rather the common programme of the chronic heart failure state; hence this invention postulates a role for treating chronic heart failure at the distinct juncture b.
  • perhexiline-induced metabolic modification may be beneficial to treatment of the stereotyped chronic heart failure state irrespective of its effect on the inciting aetiology.
  • the corollary of this assertion would be that if indeed the effect of perhexiline is as a metabolic modifier of CHF rather than a simple anti-ischaemic agent; its benefit in both ischaemically-induced CHF and non-ischaemically induced CHF would be similar.
  • the invention is supported by the first clinical data to show that any metabolic modifier (perhexiline in this case) is capable of improving human chronic heart failure; furthermore the hypothesis is supported by the finding that the benefit of perhexiline in patients having ischaemic or non-ischaemic heart failure as assessed by improvements in a number of key indicators associated with chronic heart failure, was remarkably similar.
  • FIG. 1 shows how there is an inciting phase of heart failure.
  • FIG. 2 shows 31 P MRS spectra of a right calf muscle at rest, during and after exercise.
  • FIG. 3 shows data for primary and secondary end-points as discussed in the “Results” section.
  • FIG. 4 shows data for primary and secondary end-points as discussed in the “Results” section.
  • a method of treating chronic heart failure which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said chronic heart failure.
  • the animal is preferably a mammal and most preferably a human.
  • said chronic heart failure may be chronic heart failure as a result of an initial inciting influence of ischaemia.
  • said chronic heart failure may be as a result of an initial nonischaemic inciting influence, that is to say, chronic heart failure in the absence of significant coronary artery disease, as for example may be determined by coronary angiography.
  • the use of perhexiline in the manufacture of a medicament to treat chronic heart failure is provided.
  • the medicament is for the treatment of non-ischaemic chronic heart failure, that is chronic heart failure in the substantial absence of inciting ischaemia.
  • the medicament is for the treatment of chronic heart failure having an ischaemic inciting origin.
  • the perhexiline exists in the form of a salt of perhexiline, preferably the maleate salt.
  • the perhexiline may be sued at doses in the normal therapeutic range for perhexiline (Kennedy J A, Kiosoglous A J, Murphy G A, Pelle M A, Horowitz J D. “Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart”, J Cardiovasc Pharmacal 2000; 36(6):794-801).
  • Physiologically acceptable formulations such as salts, of the compound perhexiline, may be used in the invention.
  • a medicament may be formulated for administration in any convenient way and the invention therefore also includes within its scope use of the medicament in a conventional manner in a mixture with one or more physiologically acceptable carriers or excipients.
  • the carriers should be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the medicament may be formulated for oral, buccal, parental, intravenous or rectal administration. Additionally, or alternatively, the medicament may be formulated in a more conventional form such as a tablet, capsule, syrup, elixir or any other known oral dosage form.
  • a treatment programme for treating chronic heart failure which involves the co-use or coadministration of perhexiline with one or more other compounds that are advantageous in treating chronic heart failure or the symptoms thereof.
  • the programme is for the treatment of non-ischaemic chronic heart failure, that is chronic heart failure in the substantial absence of inciting ischaemia.
  • the programme is for the treatment of chronic heart failure having an ischaemic inciting origin.
  • Patients were then allocated to two groups (ischemic or non-ischemic) depending on the presence or absence of significant coronary artery disease during coronary angiography.
  • Incremental exercise testing with assessment of respiratory gas exchange was performed on a treadmill using the Weber protocol. Breath by breath respiratory gases were measured during exercise using a Pulmolab EX670 system mass spectrometer which was calibrated before every study. Raw data were averaged to 30 second intervals and oxygen consumption during peak exercise was obtained (V0 2 max; ml/kg/min). Electrocardiograms and blood pressure were monitored throughout. Exercise was terminated at the subject's request due to fatigue or breathlessness.
  • a standard 21-question MLHFQ was employed to determine if perhexiline affected patient quality of life. This is a well validated measure of symptomatology in heart failure ( 17 ) and includes questions to assess the ability to perform activities of daily living as well as questions gauging the severity of symptoms due to heart failure. Each question was scored out of 5. The sum of the scores were calculated where a higher score indicated a poorer quality of life. All patients completed the questionnaires alone and without assistance.
  • Echocardiography was performed with patients in the left lateral decubitus position using a Vingmed System V echocardiographic machine and a 2.5 MHz transducer. Images were stored digitally. Resting scans were acquired using standard echocardiographic windows for LVEF, transmitral valve Doppler, and resting tissue Doppler. Tissue Doppler echocardiography allows objective assessment of regional wall motion and is superior to conventional grey-scale echocardiography when used in conjunction with dobutamine stress ( 18 ).
  • the ratio of peak E wave from transmitral valve Doppler vs. the E wave from tissue Doppler of the lateral mitral valve annulus is a sensitive indicator of left ventricular end diastolic pressure ( 19 ).
  • Tissue Doppler assessment of the left ventricle was performed at rest and analysed off-line using Echopac software in order to determine regional myocardial PSV from 15 left ventricular segments described in detail elsewhere ( 20 ). These segments were selected to include all areas supplied by the three major coronary arteries and for the greatest reproducibility for acquisition of PSV ( 21 ). (See FIG. 4 )
  • dobutamine infusion was commenced via a syringe driver and incremented at 3 minute intervals from 5 mcg/kg/min to 10, 20, 30 and 40 mcg/kg/min.
  • Digital loops of 15 views outlined above were stored at 90 seconds of each stage. Up to 1 mg of atropine was given if the hemodynamic response was submaximal. Electrocardiograms and blood pressure were monitored at each stage. End-points for termination of the test were attainment of ⁇ 85% of the target heart rate, evidence of ischemia, or severe side effects from dobutamine. Data from all stages were analysed off-line as with the resting images.
  • PSV data are expressed as velocity at rest, low dose dobutamine infusion (10 mls/kg/min) and peak dose dobutamine infusion (the last infusion stage before infusion terminated, which may include the addition of atropine).
  • Skeletal muscle high-energy phosphate metabolism was measured using a 2-Tesla superconducting whole-body magnet interfaced to a Bruker Avance spectrometer at least 3 days after the peak exercise tolerance test. The methodology has been described in detail elsewhere ( 23 ).
  • Phosphocreatine concentrations were quantified using a time-domain fitting routine (VARPRO, R. de Beer).
  • PCr t1 ⁇ 2 Phosphocreatine recovery halftime following exercise (PCr t1 ⁇ 2), a marker of skeletal muscle mitochondrial function which is independent of skeletal muscle mass and exercise intensity, was calculated as previously described( 24 ).
  • the primary end-point for this study was pre-defined as VO 2 max with the following secondary endpoints: MLHFQ score, LVEF, E:EA ratio, resting, low dose and high dose mean PSV during stress echocardiography and PCr t1 ⁇ 2.
  • Therapy randomization of the ischemic and non-ischemic groups occurred separately but with similar protocols in order to allow for pre-hoc analysis of the primary endpoint in each group.
  • the study had a 95% power to detect a 2 ml/kg/min increase in V0 2 max in the active vs. placebo groups with a significance level of 0.05.
  • Data were analyzed with SPSS 11.5 for Windows ⁇ and expressed as mean ⁇ standard error of mean.
  • ANCOVA using baseline values as covariates was performed to test for significance of differences seen in the perhexiline vs. placebo groups following treatment. A p value of ⁇ 0.05 was taken to indicate statistical significance.
  • VO 2 max at baseline was similar in the perhexiline and placebo groups (Table 2). Following treatment, VO 2 max was unchanged in the placebo group but markedly increased by 2.7 ⁇ 0.8 ml/kg/min (16.7%) in the perhexiline group.
  • ANCOVA demonstrated a significant effect of perhexiline vs. placebo on VO 2 max; p ⁇ 0.001.
  • Exercise time tended to increase in the perhexiline group.
  • Perhexiline therapy was also associated with a significant reduction in PCr t1 ⁇ 2 (from 67 ⁇ 15 to 44 ⁇ 7 seconds; p ⁇ 0.05) in the non-ischemic group.
  • the normal range for PCr t1 ⁇ 2 in normal healthy adults is 14 to 50 seconds ( 23 ).
  • the mechanism for the improvement seen in myocardial function with perhexiline is likely to be related to inhibition of FFA uptake and a metabolic shift towards the use of glucose and lactate. This may restores the failing hearts insulin sensitivity and makes it more oxygen efficient. In addition to requiring more oxygen than glucose to generate energy, excessive FFA metabolism has other potentially detrimental effects on the heart. FFA metabolism is known to uncouple oxidative phosphorylation and suppresses glucose oxidation through a direct inhibitory action on the glycolytic pathway. This inhibition causes increases lactate and proton accumulation within myocardial cells (Lopaschuk G O, Wambolt R B, Barr R L.
  • PCr t1 ⁇ 2 is a muscle bulk and workload independent marker of skeletal muscle mitochondrial function.
  • the faster phosphocreatine recovery after exercise in the perhexiline treated patients suggested an improvement in skeletal muscle mitochondrial oxidative function. This may reflect an improvement in the heart failure syndrome and/or be a direct consequence of the metabolic substrate shift in skeletal muscle.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • External Artificial Organs (AREA)
  • Electrotherapy Devices (AREA)

Abstract

Disclosed are methods for the treatment of chronic heart failure, comprising administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said chronic heart failure. The chronic heart failure maybe non-ischaemic or ischaemic. Also disclosed is the use of perhexiline in the manufacture of a medicament to treat chronic heart failure, including chronic heart failure of a non-ischaemic origin and chronic heart failure of an ischaemic origin.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 13/244,103, filed Sep. 23, 2011, which is a continuation of U.S. application Ser. No. 10/592,250, filed on Sep. 8, 2006, (and afforded a 35 U.S.C. 371(c)(1), (c)(2), and (c)(4) requirements date of receipt of Jul. 2, 2007), which is the National Stage of International Application No. PCT/GB2004/003835, filed Sep. 7, 2004, which claims the benefit of GB 0405381.5, filed Mar. 10, 2004. The entire contents of each of the above-identified applications are incorporated herein by reference.
    • BACKGROUND OF THE INVENTION
  • Chronic heart failure (CHF) is associated with considerable morbidity and mortality despite recent advances in heart treatments. There are a number of aetiological conditions that ultimately result in chronic heart failure including coronary artery disease, different cardiomyopathies, hypertension, or valvular diseases. A detailed characterization of chronic heart failure as a clinical syndrome may be found in Hunt S A, Baker D W, Chin M H, Cinquegrani M P, Feldman A M, Francis G S, Ganiats T G, Goldstein S, Gregoratos G, Jessup M L, Noble R J, Packer M, Silver M A, Stevenson L W. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). 2001. American College of Cardiology (http://www.acc.org/clinical/guidelines/failure/hf_index.htm).
  • Coronary artery disease (obstruction or blockage of the arteries of the heart) leads to ischaemia; this is characterized by a lack of blood supply to tissues; in this case the heart. This lack of this essential oxygen and nutrients can result in the tissue becoming impaired or permanently damaged. Once damaged the cardiac tissue is unable to perform its function. As such, the strength and efficiency of the heart muscle is reduced (this is technically termed left ventricular systolic dysfunction and results in a reduced ejection fraction; a measure of the pumping capacity of the heart). In addition to its ability to damage the heart muscle; cardiac ischaemia is frequently though not invariably identified by the physical symptom of angina (in some cases—ischaemia may occur without the correlate of anginal chest pain). Angina typically occurs under circumstances that would be expected to increase the hearts workload; resulting in an increased requirement for energy. This increased energy requirement necessitates increased oxygen provision that cannot be provided in the presence of arterial blockage; causing relative ischaemia and hence pain. Exercise is a good example of this, where the output of the heart is increased but the blood supply does not match this increase in performance and thus some of the heart tissue becomes ischaemic resulting in pain. This ischaemia, despite causing pain need not invariably result in irreversible heart damage and is not invariably related to pump dysfunction. Although ischaemia can cause both angina and heart failure, the exact manifestation of ischaemia relates to its severity and time course. Ultimately ischaemia as an inciting influence for heart failure is dissociable from its capacity to cause angina; they may or may not co-exist.
  • However, a lack of blood supply is only one of the many causes for cardiac pump impairment. Other reasons include cardiac arrhythmias (abnormal heart electrical rhythms), hypertension (high blood pressure), valve diseases, infections, toxins or impairment in the nervous stimulation of the heart to name but a few.
  • While these initial insults to the heart are diverse in character and severity, their common feature is that they cause either damage to heart muscle cells (myocytes) or at least impair their ability to contract. This results in left ventricular systolic dysfunction. It is this common feature that triggers the cascade that results in the stereotyped and distinct state of chronic heart failure. As discussed in “Mechanisms and Models in Heart Failure: A Combinatorial Approach”, by Douglas L. Mann, M D, Circulation, 1999; pages 999-1008 and in “Drug Therapy: The Management of Chronic Heart Failure”, by Jay N. Cohn, M D, New England Journal of Medicine 1996; pages 490-498), heart failure may be viewed as a progressive disorder that is initiated after an index event either damages the heart muscle, with a resultant loss 15 of functioning cardiac myocytes, or alternatively disrupts the ability of the myocardium to generate force, thereby preventing the heart from contracting normally. This index event may have an abrupt onset, as in the case of a myocardial infarction (heart attack), it may have a gradual or insidious onset, as in the case hemodynamic pressure or volume overloading, or it may be hereditary, as in the case of many of the genetic cardiomyopathies.
  • Regardless and irrespective of the diverse nature of the inciting event, the feature that is common to all of these index events is that they all, in some manner, produce a decline in pumping capacity of the heart. Following the initial decline in pumping capacity of the heart, acutely, patients may become very symptomatic; they may be minimally symptomatic or may even remain asymptomatic. However, the decreased pump capacity generally results in a diminished cardiac output. This chronically activates the neurohumoral system, particularly the sympathetic nervous system, the renin-angiotensin-aldosterone system, and potentiates the release of vasopressin.
  • Although in the short term these adaptations are beneficial due to their capacity to maintain blood flow to vital organs; in the long term, these reflexes have deleterious effects and ultimately result in cardiac remodeling (FIG. 1). This remodelling is the central stereotyped feature of CHF irrespective of the inciting influence and is manifest at the macroscopic level (visible to the eye) by dilatation of the heart chambers. However there is also corresponding remodelling at the molecular and the cellular level. These include changes in cellular transcription (the genetic programmes determining cellular function) and the resulting cellular pathways. One aspect of cellular function that is altered in chronic heart failure is cellular metabolism and energy production.
  • The common unified programme of the failing heart irrespective of the inciting insult thus includes chronic energy starvation. It has been postulated that these energy changes are not simply just a feature of CHF but are of mechanistic importance in chronic heart failure. The failing heart is characterized by a marked change in substrate preference away from fatty acid metabolism toward glucose metabolism. Glucose is a more efficient cellular fuel and this particular adaptation may therefore be an adaptive feature of chronic heart failure—partially mitigating the effect of energy deficit. It therefore follows that augmentation of “metabolic remodeling” is a potential target in chronic heart failure; however to date there has been a paucity of even animal data to confirm this assertion.
  • Perhexiline (2-(2,2-dicyclohexylethyl)piperidine) is a known anti-anginal agent that operates principally by virtue of its ability to shift metabolism in the heart from free fatty acid metabolism to glucose, which is more energy efficient. Aside from being used for the treatment of angina as a manifestation of ischaemia (in patients who may or may not coincidentally have heart failure), there is no record of using perhexiline to treat instances of non-ischaemia and certainly no known use of this drug to treat instances of heart failure independent of angina. Phrased alternatively; while perhexiline has been used to treat patients with angina and ischaemia at the point where this may be an inciting influence for heart failure as demonstrated by arrow (a) in FIG. 1, (which therefore may or may not be associated with active ischaemia-related pump dysfunction or ischaemia-related congestive cardiomyopathy); there has never been a suggestion that perhexiline may be useful in the modification of chronic metabolic remodelling in the distinct stereotyped phenotype of chronic heart failure as demonstrated by arrow (b) in FIG. 1.
  • With further reference to FIG. 1, it is apparent that there is an inciting phase of heart failure, which is due to diverse initiating influences. While completely unrelated to one another, these diverse influences all result in pump failure and left ventricular systolic dysfunction. Irrespective of inciting influence, this pump failure initiates an initially adaptive but ultimately partially maladaptive remodelling. This chronic remodelling is a stereotyped molecular, cellular and macroscopic phenomenon, and the central cause of eventual progressive chronic heart failure. Chronic heart failure remodelling ultimately leads to a vicious cycle of detrimental events. Part of the chronic heart failure phenotype is energetic deficiency and a shift in cellular metabolism away from fatty acid metabolism to glucose metabolism.
    • SUMMARY OF THE INVENTION
  • Hitherto, perhexiline has been used as an anti-ischaemic agent at juncture a, the inciting phase; although even at this stage it has not been used explicitly as an antifailure agent. The present invention postulates that metabolic manipulation with perhexiline is effective in modifying not an inciting influence; but rather the common programme of the chronic heart failure state; hence this invention postulates a role for treating chronic heart failure at the distinct juncture b.
  • The present invention is thus based on the hypothesis that perhexiline-induced metabolic modification may be beneficial to treatment of the stereotyped chronic heart failure state irrespective of its effect on the inciting aetiology. The corollary of this assertion would be that if indeed the effect of perhexiline is as a metabolic modifier of CHF rather than a simple anti-ischaemic agent; its benefit in both ischaemically-induced CHF and non-ischaemically induced CHF would be similar. The invention is supported by the first clinical data to show that any metabolic modifier (perhexiline in this case) is capable of improving human chronic heart failure; furthermore the hypothesis is supported by the finding that the benefit of perhexiline in patients having ischaemic or non-ischaemic heart failure as assessed by improvements in a number of key indicators associated with chronic heart failure, was remarkably similar.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows how there is an inciting phase of heart failure.
  • FIG. 2 shows 31P MRS spectra of a right calf muscle at rest, during and after exercise.
  • FIG. 3 shows data for primary and secondary end-points as discussed in the “Results” section.
  • FIG. 4 shows data for primary and secondary end-points as discussed in the “Results” section.
    •  DETAILED DESCRIPTION OF THE INVENTION
  • According to a first aspect of the present invention, there is provided a method of treating chronic heart failure, which comprises administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said chronic heart failure. The animal is preferably a mammal and most preferably a human.
  • In one embodiment, said chronic heart failure may be chronic heart failure as a result of an initial inciting influence of ischaemia.
  • In another embodiment, said chronic heart failure may be as a result of an initial nonischaemic inciting influence, that is to say, chronic heart failure in the absence of significant coronary artery disease, as for example may be determined by coronary angiography.
  • According to another aspect of the present invention, there is provided the use of perhexiline in the manufacture of a medicament to treat chronic heart failure. In one embodiment, the medicament is for the treatment of non-ischaemic chronic heart failure, that is chronic heart failure in the substantial absence of inciting ischaemia. In another embodiment, the medicament is for the treatment of chronic heart failure having an ischaemic inciting origin.
  • In aspects of the present invention, the perhexiline exists in the form of a salt of perhexiline, preferably the maleate salt. The perhexiline may be sued at doses in the normal therapeutic range for perhexiline (Kennedy J A, Kiosoglous A J, Murphy G A, Pelle M A, Horowitz J D. “Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart”, J Cardiovasc Pharmacal 2000; 36(6):794-801).
  • Physiologically acceptable formulations, such as salts, of the compound perhexiline, may be used in the invention. Additionally, a medicament may be formulated for administration in any convenient way and the invention therefore also includes within its scope use of the medicament in a conventional manner in a mixture with one or more physiologically acceptable carriers or excipients. Preferably, the carriers should be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. The medicament may be formulated for oral, buccal, parental, intravenous or rectal administration. Additionally, or alternatively, the medicament may be formulated in a more conventional form such as a tablet, capsule, syrup, elixir or any other known oral dosage form.
  • According to a further aspect of the invention there is provided a treatment programme for treating chronic heart failure, which involves the co-use or coadministration of perhexiline with one or more other compounds that are advantageous in treating chronic heart failure or the symptoms thereof. In one embodiment, the programme is for the treatment of non-ischaemic chronic heart failure, that is chronic heart failure in the substantial absence of inciting ischaemia. In another embodiment, the programme is for the treatment of chronic heart failure having an ischaemic inciting origin.
    • EXAMPLE
  • An embodiment of the invention will now be described by way of example only wherein a double-blind, randomised, placebo-controlled study was undertaken in order to investigate the effects of perhexiline on chronic heart failure. 56 patients with CHF were recruited and all provided written informed consent. Entry criteria were as follows: left ventricular ejection fraction (LVEF) <40%, optimally medicated heart failure with New York Heart Association (NYHA) Class II-III symptoms. Cardiopulmonary exercise testing with respiratory gas analysis, completion of the Minnesota Living with Heart Failure Questionnaire. (MLHFQ) and 2-D echocardiography were performed at baseline on all patients.
  • Patients were then allocated to two groups (ischemic or non-ischemic) depending on the presence or absence of significant coronary artery disease during coronary angiography.
  • The ischemic group (n=30) was also subjected to dobutamine stress echocardiography at baseline. The non-ischemic group (n=26) was subjected to 31P magnetic resonance spectroscopy to measure changes in muscle mitochondrial function.
    • All Patients: Cardiopulmonary Exercise Test
  • Incremental exercise testing with assessment of respiratory gas exchange was performed on a treadmill using the Weber protocol. Breath by breath respiratory gases were measured during exercise using a Pulmolab EX670 system mass spectrometer which was calibrated before every study. Raw data were averaged to 30 second intervals and oxygen consumption during peak exercise was obtained (V02max; ml/kg/min). Electrocardiograms and blood pressure were monitored throughout. Exercise was terminated at the subject's request due to fatigue or breathlessness.
  • Minnesota Living with Heart Failure Questionnaire (MLHFQ)
  • A standard 21-question MLHFQ was employed to determine if perhexiline affected patient quality of life. This is a well validated measure of symptomatology in heart failure (17) and includes questions to assess the ability to perform activities of daily living as well as questions gauging the severity of symptoms due to heart failure. Each question was scored out of 5. The sum of the scores were calculated where a higher score indicated a poorer quality of life. All patients completed the questionnaires alone and without assistance.
    • Resting Echocardiography
  • Echocardiography was performed with patients in the left lateral decubitus position using a Vingmed System V echocardiographic machine and a 2.5 MHz transducer. Images were stored digitally. Resting scans were acquired using standard echocardiographic windows for LVEF, transmitral valve Doppler, and resting tissue Doppler. Tissue Doppler echocardiography allows objective assessment of regional wall motion and is superior to conventional grey-scale echocardiography when used in conjunction with dobutamine stress (18).
  • Left ventricular volumes for calculation of LVEF were obtained using biplane echocardiography and the modified Simpson's formula. Volumes were averaged over 3 beats. In addition, on-line tissue Doppler peak systolic velocity (PSV) of the lateral mitral valve annulus was obtained as a reflection of left ventricular long-axis function.
  • In theory, improving metabolic efficiency would also lead to an improvement in diastolic function of the left ventricle as energy is also required for cardiac relaxation. The ratio of peak E wave from transmitral valve Doppler vs. the E wave from tissue Doppler of the lateral mitral valve annulus (E:EA ratio) is a sensitive indicator of left ventricular end diastolic pressure (19).
    • Ischemic Group:
  • Tissue Doppler assessment of the left ventricle was performed at rest and analysed off-line using Echopac software in order to determine regional myocardial PSV from 15 left ventricular segments described in detail elsewhere (20). These segments were selected to include all areas supplied by the three major coronary arteries and for the greatest reproducibility for acquisition of PSV (21). (See FIG. 4)
    • Dobutamine Stress Echocardiography
  • Following resting echocardiography dobutamine infusion was commenced via a syringe driver and incremented at 3 minute intervals from 5 mcg/kg/min to 10, 20, 30 and 40 mcg/kg/min. Digital loops of 15 views outlined above were stored at 90 seconds of each stage. Up to 1 mg of atropine was given if the hemodynamic response was submaximal. Electrocardiograms and blood pressure were monitored at each stage. End-points for termination of the test were attainment of ≧85% of the target heart rate, evidence of ischemia, or severe side effects from dobutamine. Data from all stages were analysed off-line as with the resting images.
  • PSV data are expressed as velocity at rest, low dose dobutamine infusion (10 mls/kg/min) and peak dose dobutamine infusion (the last infusion stage before infusion terminated, which may include the addition of atropine).
    • Non-Ischemic Group: 31P Magnetic Resonance Spectroscopy
  • Patients with CHF have abnormally rapid skeletal muscle phosphocreatine (a high energy phosphate metabolite critically involved in muscle contraction) depletion during exercise with delayed recovery(22). 31P magnetic resonance spectroscopy allows changes in skeletal muscle intracellular high energy phosphate compounds and pH to be measured non-invasively. At the end of exercise, because glycogenolysis has stopped and phosphocreatine resynthesis is purely oxidative, analysis of phosphocreatine recovery provides information about skeletal muscle mitochondrial function. In order to determine the effect of augmenting glucose metabolism on muscle energetics, magnetic resonance spectroscopy of calf muscle before, during and after local exercise was performed. Only patients in the nonischemic heart failure population were subjected to magnetic resonance spectroscopy as underlying peripheral vascular disease leads to abnormalities in skeletal muscle energetics independent of heart failure.
  • Skeletal muscle high-energy phosphate metabolism was measured using a 2-Tesla superconducting whole-body magnet interfaced to a Bruker Avance spectrometer at least 3 days after the peak exercise tolerance test. The methodology has been described in detail elsewhere (23).
  • Briefly, subjects were positioned within the magnet in the supine position with a 6 cm diameter surface coil under the maximal circumference of the right calf muscle. 31Phosphorus spectra were collected at rest, during exercise and recovery. Following spectral acquisition at rest, a standardized exercise protocol was employed which involved plantar flexion at 0.5 Hz lifting 10% of lean body mass a distance of 7 cm. This workload was continued for 4 minutes before being incremented by 2% of lean body mass for every subsequent minute until fatigue or phosphocreatine hydrolysis reached 50% of the resting level. Recovery spectra were subsequently acquired for 11 minutes. Examples of the spectra obtained during a typical study are shown in FIG. 3.
  • Phosphocreatine concentrations were quantified using a time-domain fitting routine (VARPRO, R. de Beer). Phosphocreatine recovery halftime following exercise (PCr t½), a marker of skeletal muscle mitochondrial function which is independent of skeletal muscle mass and exercise intensity, was calculated as previously described(24).
    • Intervention
  • Following baseline studies, patients were randomized in a double-blind fashion to receive either perhexiline (n=28) or placebo (n=28) 100 mg twice daily. Blood was obtained at 1, 4, and 8 weeks after initiation of the drug for measurements of serum perhexiline levels with subsequent dose titration in order to prevent toxicity. Dose adjustments were advised as per a standard protocol by an unblinded physician. Identical dosage adjustments were also made for randomly allocated placebo-treated patients by the unblinded observer in order to ensure blinding of the investigators was maintained. After 8 weeks of treatment, patients were re-evaluated as above.
    • Statistics
  • The primary end-point for this study was pre-defined as VO2max with the following secondary endpoints: MLHFQ score, LVEF, E:EA ratio, resting, low dose and high dose mean PSV during stress echocardiography and PCr t½. Therapy randomization of the ischemic and non-ischemic groups occurred separately but with similar protocols in order to allow for pre-hoc analysis of the primary endpoint in each group. The study had a 95% power to detect a 2 ml/kg/min increase in V02max in the active vs. placebo groups with a significance level of 0.05. Data were analyzed with SPSS 11.5 for Windows© and expressed as mean±standard error of mean. ANCOVA using baseline values as covariates was performed to test for significance of differences seen in the perhexiline vs. placebo groups following treatment. A p value of <0.05 was taken to indicate statistical significance.
    • Results
  • All patients completed the 8-week course of treatment. There were no deaths in either group during the study period. Side effects in the perhexiline group were restricted to transient nausea and dizziness during the first week of treatment (n=3).
  • Both groups were well matched for baseline characteristics and treatment (Table 1). There was a significant fall in the NYHA class within the perhexiline group after treatment (p=0.02).
  • VO2max at baseline was similar in the perhexiline and placebo groups (Table 2). Following treatment, VO2max was unchanged in the placebo group but markedly increased by 2.7±0.8 ml/kg/min (16.7%) in the perhexiline group. ANCOVA demonstrated a significant effect of perhexiline vs. placebo on VO2max; p<0.001. The increase in VO2max in the ischemic and non-ischemic group were 2.9±1.2 ml/kg/min (p=0.008) and 2.5±0.4 ml/kg/min (p=0.03) respectively. Exercise time tended to increase in the perhexiline group.
  • MLHFQ scores were significantly reduced by 24.4% following treatment in the perhexiline group (p=0.04) but unchanged in the placebo group. Perhexiline therapy was also associated with a significant reduction in PCr t½ (from 67±15 to 44±7 seconds; p<0.05) in the non-ischemic group. The normal range for PCr t½ in normal healthy adults is 14 to 50 seconds (23).
  • Mean LVEF was also markedly increased following treatment in the perhexiline group (by 9.9+2.0 absolute percentage points, a relative increase of 42%) and unchanged in the placebo group (p<0.001). Whilst left ventricular diastolic volume tended to decrease in the perhexiline group (p=0.06), systolic volume was significantly reduced (p<0.001) suggesting an increase in myocardial contractility. There was a significant reduction in E:EA ratio following treatment with perhexiline reflecting a reduction in left ventricular end diastolic pressure. In addition long-axis systolic function was increased in the perhexiline group reflecting an improvement in subendocardial function.
  • Within the ischemic cohort, there was no significant difference in heart rate at rest or during dobutamine stress in both groups. However, there was a significant 15% (p=0.04) increase in resting mean PSV in the perhexiline group following treatment. This increase reflects the increases seen in long-axis function and LVEF. During tissue Doppler stress echocardiography; there was a trend towards an increase in PSV at baseline (p=0.07) in the perhexiline group but a marked increase in peak dose PSV (24% p=0.03). At lower doses of dobutamine the myocardial velocities are inevitably lower; these low velocities are further diminished when measured off-line when compared to those obtained on-line by pulsed tissue Doppler. This is because they are derived from regional mean velocities rather than peak velocities. Though standard practice; this diminution will artificially appear to diminish the significance of the differences at low myocardial velocities. This explains the contrast between the seemingly small differences in baseline and low dose stress tissue Doppler parameters compared to the consistent and large increases in LVEF and online PSV of the lateral mitral annulus.
  • The data for the primary and secondary end-points are depicted on FIGS. 3 and 4 and summarized on Table 2.
    • Discussion
  • As a result of these experiments, it was found that Perhexiline use resulted in significant improvements in peak exercise capacity, myocardial function at rest and stress, patient reported symptoms and skeletal muscle energetics. Remarkably; as well as being statistically highly significant, these improvements represent clinically significant improvements in patients who were already optimally treated. Our results suggest that perhexiline provides consistent improvements in these parameters, in the absence of significant side effects, irrespective of the initial inciting influence of CHF.
  • Without wishing to be bound by theory, the mechanism for the improvement seen in myocardial function with perhexiline is likely to be related to inhibition of FFA uptake and a metabolic shift towards the use of glucose and lactate. This may restores the failing hearts insulin sensitivity and makes it more oxygen efficient. In addition to requiring more oxygen than glucose to generate energy, excessive FFA metabolism has other potentially detrimental effects on the heart. FFA metabolism is known to uncouple oxidative phosphorylation and suppresses glucose oxidation through a direct inhibitory action on the glycolytic pathway. This inhibition causes increases lactate and proton accumulation within myocardial cells (Lopaschuk G O, Wambolt R B, Barr R L. “An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts”, J Pharmacal Exp Ther 1993; 264(1):135-144) leading to a fall in intracellular pH which is associated with a reduction in contractile function (Hausch G. “Hibernating myocardium”, Physiol Rev 1998; 78(4):1055-1085). Furthermore, FFA metabolite accumulation have been shown to reduce ventricular arrhythmia threshold (Murnaghan M F. “Effect of fatty acids on the ventricular arrhythmia threshold in the isolated heart of the rabbit” Br J Pharmacal 1981; 73(4):909-915) and induce diastolic dysfunction (Depre C, Vanoverschelde J L, Taegtmeyer H. “Glucose for the heart”, Circulation 1999; 99(4):578-588.).
  • The anti-anginal efficacy of perhexiline, both as mono- and combined therapy, is well documented (Horowitz J D, Mashford M L. “Perhexiline maleate in the treatment of severe angina pectoris”, Med J Aust 1979; 1 (11):485-488; Cole P L, Beamer A D, McGowan N, Cantillon C O, Benfell K, Kelly R A et al. “Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent”, Circulation 1990; 81(4):1260-1270). However, use of the drug declined due to reports of hepatotoxicity and peripheral neuropathy. It is now apparent that the risk of toxicity was related to the ability to metabolize the drug. ‘Slow hydroxylators’, with a genetic variant of the cytochrome P450-2D6, are particularly prone to progressive drug accumulation. In the absence of dosage adjustment; prolonged elevation of levels leads to phospholipid accumulation which may also occur with prolonged use of other CPT inhibitors, such as amiodarone. The risk of development of hepato-neuro-toxicity with perhexiline is markedly reduced by monitoring and maintaining serum levels between 0.15 and 0.60 mg/l. None of the patients in this study developed abnormal liver function tests or neuropathy as a consequence of perhexiline treatment followed by close serum level monitoring and titration.
  • 31P magnetic resonance spectroscopy was included in the study design to determine whether perhexiline treatment also improved skeletal muscle energetics. PCr t½ is a muscle bulk and workload independent marker of skeletal muscle mitochondrial function. The faster phosphocreatine recovery after exercise in the perhexiline treated patients suggested an improvement in skeletal muscle mitochondrial oxidative function. This may reflect an improvement in the heart failure syndrome and/or be a direct consequence of the metabolic substrate shift in skeletal muscle.
  • The results of the current study therefore establish that perhexiline exerts incremental benefits on symptomatic status, left ventricular function at rest and peak stress, and skeletal muscle metabolism in patients with stable chronic heart failure, over and above standard neurohumoral therapy. Indeed, the improvements in VO2max were comparable to those seen in patients treated with beta-blockers (Hulsmann M, Sturm B, Pacher R, Berger R, Bojic A, Frey B et al. “Long-term effect of atenolol on ejection fraction, symptoms, and exercise variables in patients with advanced left ventricular dysfunction”, J Heart Lung Transplant 2001; 20(11):1174-10 1180) but exceeded those seen with ACE inhibitors (Vescovo G, Della L L, Serafini F, Leprotti C, Facchin L, Volterrani M et al. <<Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition”, Circulation 1998; 98(17):1742-1749), spironolactone (Cicoira M, Zanella L, Rossi A, Golia G, Franceschini L, Brighetti G et al. “Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure”, J Am Coli Cardiel 2002; 40(2):304-310) or even with biventricular pacing (Auricchio A, Stellbrink C, Butter C, Sack S, Vogt J, Misier A R et al. “Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay”, J Am Coli Cardiel 2003; 42(12):2109-2116). As this study included patients with and without significant coronary artery disease who all benefited, the benefit cannot therefore be ascribed purely to an anti-ischemic mechanism, rather, it is suggestive of our hypothesis that Perhexiline is modifying the central metabolic remodeling of CHF.
  • The contents of all references cited herein are hereby incorporated herein in their entirety for all purposes.
  • TABLE 1
    Baseline characteristics and treatment
    Placebo Group Perhexiline Group
    N 28  28 
    Ischemic:Non Ischemic 13:15 13:15
    Age 63 ± 2 63 ± 2
    Sex (M:F) 23:5  27:1 
    Weight (kg) 83 ± 3 89 ± 3
    Height (cm) 165 ± 6 cm 175 ± 2 cm
    Body mass index 28 ± 1  29 ± 1 
    NYHA Class
    Pre:  2.2 ± 0.1 2.4 ± 0.1
    Post:  2.1 ± 0.1  1.9 ± 0.2+
    Corrected QT interval
    Pre: 421 ± 7 ms 413 ± 11 ms 
    Post: 421 ± 9 ms 413 ± 13 ms 
    Diabetes 2 5
    Loop Diuretic 20  17 
    ACE Inhibitor 25  22 
    Lisinopril (mean dose)  22 ± 4 mg  23 ± 3 mg
    Ramipril 10 mg  8.3 ± 1 mg
    Perindopril  6 mg  6 mg
    Enalapril 22 ± 10 mg  15 ± 5 mg
    Trandolapril  4 mg  4 mg
    AT2 Receptor Blockers 4 3
    Losartan 63 ± 38 mg 100 mg 
    Valsartan 80 mg 80 mg
    Irbersartan 175 ± 125 mg  —
    Beta-Blockers 15  18 
    Carvedilol 37 ± 10 mg 50 mg
    Bisoprolol  2 ± 0.4 mg  4 ± 1 mg
    Metoprolol 75 ± 25 mg 100 mg 
    Atenolol 67 ± 17 mg 69 ± 19 mg
    Aspirin 15  11 
    Clopidogrel 1 3
    Warfarin 9 9
    Calcium Channel Blockers 5 3
    Spironolactone (mean dose) 7 (21 ± 4 mg) 6 (23 ± 2 mg)
    Amiodarone 4 1
    Oral Hypoglycaemics 1 2
    Insulin 0 2
    Statin 18  12 
    Serum perhexiline levels:
    Week 1: 0 0.57 ± 0.19 mg/l 
    Week 4: 0 0.67 ± 0.20 mg/l 
    Week 8: 0 0.43 ± 0.12 mg/l 
    +p = 0.02
  • TABLE 2
    Primary and secondary endpoints. (All P values refer to AN CO
    VA of the differential effect of perhexiline vs. placebo)
    Perhexiline
    Placebo Group Group P value
    VO2max (ml/kg/min)
    Pre: 16.3 ± 0.8 16.1 ± 0.6 *<0.001
    Post: 16.0 ± 0.9  18.8 ± 1.1*
    Exercise Time (mins)
    Pre:  9.9 ± 1.2 10.5 ± 1.2
    Post: 10.9 ± 0.9 12.3 ± 1.1
    Respiratory exchange ratio
    during peak exercise+
    Pre:  1.1 ± 0.02  1.1 ± 0.03
    Post:  1.1 ± 0.02  1.1 ± 0.03
    Resting BP (mmHg)
    Pre: 111/63 ± 5/3  116/69 ± 7/4 
    Post 113/67 ± 5/4  113/67 ± 7/4 
    Peak Exercise BP (mmHg)
    Pre: 141/69 ± 5/4  141/75 ± 9/3 
    Post: 137/68 ± 7/4  142/70 ± 9/5 
    Resting Heart Rate(min−1)
    Pre: 76 ± 4 73 ± 3
    Post: 78 ± 4 73 ± 3
    Peak Exercise
    Heart Rate(min−1)
    Pre: 124 ± 6  121 ± 6 
    Post: 121 ± 5  120 ± 5 
    Minnesota living with heart
    failure questionnaire score
    Pre: 42 ± 5 45 ± 5 †0.04
    Post: 40 ± 4  34 ± 5†
    Left ventricular
    end-diastolic volume (ml)
    Pre: 213 ± 16 232 ± 11
    Post: 216 ± 16 212 ± 9 
    Left ventricular
    end-systolic volume (ml)
    Pre: 159 ± 13 176 ± 8  ‡<0.001
    Post: 162 ± 14 140 ± 8‡ 
    Left ventricular
    ejection fraction (%)
    Pre: 26 ± 1 24 ± 1 §<0.001
    Post 26 ± 1  34 ± 2§
    Long axis function (cm/s)
    Pre:  6.4 ± 0.6  5.8 ± 0.4 ||0.04
    Post:  6.4 ± 0.5  7.2 ± 0.6||
    E:EA Ratio
    Pre:  8.3 ± 1.0  8.8 ± 0.6# #0.02
    Post:  8.9 ± 1.8 6.5 ± 0.9
    PCr 1½ (seconds)
    Pre:  58 ± 10  67 ± 15 **<0.05
    Post:  73 ± 24  44 ± 7**
    Dobutamine Stress
    Echocardiography:
    Heart Rate:
    Rest Pre 67 ± 5 57 ± 2
    Post 66 ± 6 53 ± 2
    Low Dose Pre 86 ± 8 78 ± 7
    Post 74 ± 6 65 ± 6
    Peak Dose Pre 130 ± 5  126 ± 4 
    Post 128 ± 5  122 ± 3 
    Mean PSV
    (15 segments)
    Rest Pre  3.5 ± 0.2  3.3 ± 0.2 ††0.07
    Post  3.4 ± 0.2   3.8 ± 0.2†† §§0.003
    Low Dose Pre  4.6 ± 0.3  4.7 ± 0.3
    Post  4.8 ± 0.3  5.0 ± 0.5
    Peak Dose Pre  6.4 ± 0.4  6.6 ± 0.5
    Post  5.8 ± 0.4   8.2 ± 0.8§§
    +Ratio of CO2 emission/oxygen consumption

Claims (21)

What is claimed is:
1. A method for treating a mammal having chronic heart failure or a symptomatic component/feature/condition thereof due to or associated with a member of the group consisting of: ischaemia, coronary artery disease, cardiomyopathy, hypertension, diabetes, and valvular disease, the method comprising:
diagnosing the mammal as having chronic heart failure or a symptomatic component/feature/condition thereof; and
administering to said mammal a therapeutically-effective amount of perhexiline.
2. The method of claim 1, wherein the therapeutically-effective amount of perhexiline is sufficient to reduce or ameliorate the chronic heart failure or a symptomatic component/feature/condition thereof in the mammal.
3. The method of claim 1, wherein the perhexiline is in the form of a pharmaceutically acceptable salt.
4. The method of claim 2, wherein the perhexiline is in the form of a maleate salt.
5. The method of claim 1, wherein the mammal is a human.
6. The method of claim 1, further comprising co-administering to said mammal at least one therapeutic compound.
7. The method of claim 1, further comprising co-administering to said mammal at least one therapeutic compound advantageous in treating chronic heart failure or a symptomatic component/feature/condition thereof.
8. The method of claim 6, wherein the therapeutic compound is selected from a member of the group consisting of Alpha Blockers, Beta Blockers, Calcium Channel Blockers, Diuretics, Ace (Angiotensin-Converting Enzyme) Inhibitors, Arb (Angiotensin II Receptor Blockers), Spironolactone, Nitrate, Warfarin, Verapamil, Insulin, Amiodarone, Lisinopril, Ramipril, Perindopril, Enalapril, Trandolapril, At2 Receptor Blockers, Losartan, Valsartan, Irbersartan, Carvedilol, Bisoprolol, Metoprolol, Atenolol, Aspirin, Clopidogrel, Oral Hypoglycaemics, Disopyramide, and Statins.
9. The method of claim 1, wherein the symptomatic component/feature/condition is member of the group consisting of dyspnoea (shortness of breath), chest pain, fatigue, palpitation, and syncope.
10. The method of claim 1, wherein the symptomatic component/feature/condition is member of the group consisting of reduced left ventricular ejection fraction (LVEF), reduced E:EA ratio, abnormally rapid skeletal muscle phosphocreatine depletion with delayed recovery, reduced systolic velocity (PSV), diminished exercise capacity or tolerance, diminished peak oxygen consumption (VO2max) during exercise, and impaired myocardial energetic state (PCr/γATP ratio).
11. The method of claim 1, wherein the extent of chronic heart failure in the mammal is diagnosed in accordance with the New York Heart Association (NYHA) diagnostic system.
12. The method of claim 9, further comprising:
determining a NYHA classification score (breathlessness) of the mammal before and after administration of perhexline, wherein a decreased NYHA score after administration of perhexline indicates a reduction in the extent of chronic heart failure or a symptomatic component/feature/condition thereof in the mammal.
13. The method of claim 12, wherein the NYHA classification score of the mammal after administration of perhexline decreases from Class III to Class II.
14. The method of claim 1, wherein the extent of chronic heart failure in the mammal is diagnosed in accordance with the Minnesota Living with Heart Failure Questionnaire (MLHFQ) scoring system.
15. The method of claim 14, further comprising
determining a MLHFQ (quality of life) score of the mammal before and after administration of perhexline, wherein a decreased MLHFQ score after administration of perhexline indicates a reduction in the extent of chronic heart failure or a symptomatic component/feature/condition thereof in the mammal.
16. The method of claim 1, further comprising
determining peak oxygen consumption (VO2max) in the mammal during exercise wherein an increase in peak oxygen consumption (VO2max) in the mammal after administration of perhexline indicates a reduction in the extent of chronic heart failure or a symptomatic component/feature/condition thereof in the animal.
17. The method of claim 1, wherein perhexiline is administered in an amount of 300 mg per day or less.
18. The method of claim 1, wherein perhexiline is administered in an amount of 100 mg per day or less.
19. The method of claim 1, wherein perhexiline is administered in an amount of 100 mg to 300 mg per day.
20. The method of claim 1, further comprising: monitoring and maintaining serum levels of perhexiline in said mammal in a range of about 0.15 and about 0.60 mg/l.
21. A method for treating chronic heart failure substantially as described in the specification, Tables and Examples, with reference to each of the accompanying Figures.
US13/841,635 2004-03-10 2013-03-15 Perhexiline for treating chronic heart failure Abandoned US20130331321A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/841,635 US20130331321A1 (en) 2004-03-10 2013-03-15 Perhexiline for treating chronic heart failure

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0405381.5 2004-03-10
GBGB0405381.5A GB0405381D0 (en) 2004-03-10 2004-03-10 A method and means for treating heart failure
PCT/GB2004/003835 WO2005087233A1 (en) 2004-03-10 2004-09-07 Perhexilin for treating chronic heart failure
US59225007A 2007-07-02 2007-07-02
US13/244,103 US8470806B2 (en) 2004-03-10 2011-09-23 Perhexiline for treating chronic heart failure
US13/841,635 US20130331321A1 (en) 2004-03-10 2013-03-15 Perhexiline for treating chronic heart failure

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/244,103 Continuation US8470806B2 (en) 2004-03-10 2011-09-23 Perhexiline for treating chronic heart failure

Publications (1)

Publication Number Publication Date
US20130331321A1 true US20130331321A1 (en) 2013-12-12

Family

ID=32117402

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/592,250 Abandoned US20070275997A1 (en) 2004-03-10 2004-09-07 Perhexiline For Treating Chronic Heart Failure
US13/244,103 Expired - Fee Related US8470806B2 (en) 2004-03-10 2011-09-23 Perhexiline for treating chronic heart failure
US13/841,635 Abandoned US20130331321A1 (en) 2004-03-10 2013-03-15 Perhexiline for treating chronic heart failure
US13/841,465 Expired - Fee Related US8697677B2 (en) 2004-03-10 2013-03-15 Perhexiline for treating chronic heart failure

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/592,250 Abandoned US20070275997A1 (en) 2004-03-10 2004-09-07 Perhexiline For Treating Chronic Heart Failure
US13/244,103 Expired - Fee Related US8470806B2 (en) 2004-03-10 2011-09-23 Perhexiline for treating chronic heart failure

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/841,465 Expired - Fee Related US8697677B2 (en) 2004-03-10 2013-03-15 Perhexiline for treating chronic heart failure

Country Status (13)

Country Link
US (4) US20070275997A1 (en)
EP (1) EP1732551B1 (en)
JP (1) JP5087389B2 (en)
CN (1) CN1950084A (en)
AT (1) ATE487480T1 (en)
DE (1) DE602004030048D1 (en)
DK (1) DK1732551T3 (en)
ES (1) ES2358514T3 (en)
GB (1) GB0405381D0 (en)
MX (1) MXPA06010397A (en)
PL (1) PL1732551T3 (en)
PT (1) PT1732551E (en)
WO (1) WO2005087233A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457017B2 (en) 2007-11-23 2016-10-04 Heart Metabolics Limited Treatment of heart failure

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0405381D0 (en) 2004-03-10 2004-04-21 Univ Wales Medicine A method and means for treating heart failure
GB0723100D0 (en) * 2007-11-23 2008-01-02 Heart Metabolics Ltd Treatment of HFnEF
GB0908193D0 (en) * 2009-05-13 2009-06-24 Albright Patents Treatment of disease state
US9393221B2 (en) 2011-07-20 2016-07-19 The General Hospital Corporation Methods and compounds for reducing intracellular lipid storage
AU2013313021A1 (en) * 2012-09-05 2015-03-26 Adelaide Research & Innovation Pty Ltd Uses of (-)-perhexiline
CN102988347A (en) * 2012-11-19 2013-03-27 何晓涛 Application of Aphanamixoid A for preparing medicine for treating or preventing chronic heart failure
GB201308736D0 (en) * 2013-05-15 2013-06-26 Univ Aberdeen Compounds and their therapeutic use
JP2015147787A (en) * 2015-04-01 2015-08-20 ハート メタボリクス リミテッド Treatment of heart failure with normal ejection fraction
US20230047313A1 (en) * 2019-12-16 2023-02-16 Children`S Medical Center Corporation Treating heart disease in muscular dystrophy patients

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN380695A0 (en) * 1995-06-23 1995-07-20 Queen Elizabeth Hospital, The Methods related to the treatment of and isolation of compounds for treatment of ischaemic conditions
US20030162824A1 (en) * 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
CL2004000366A1 (en) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USE OF A COMBINATION OF A QUINASA P38 INHIBITING DERIVED COMPOUND OF PIRAZOL, AND AN ACE INHIBITOR TO TREAT RENAL DYSFUNCTION, CARDIOVASCULAR AND VASCULAR DISEASE, RETINOPATHY, NEUROPATIA, EDOTEL, INSOTUNATIO OPINION.
GB0405381D0 (en) 2004-03-10 2004-04-21 Univ Wales Medicine A method and means for treating heart failure
WO2005097121A1 (en) 2004-04-06 2005-10-20 Angiogenetics Sweden Ab Angiogenesis-affecting compounds and methods of use thereof
GB0723100D0 (en) 2007-11-23 2008-01-02 Heart Metabolics Ltd Treatment of HFnEF
WO2010133815A1 (en) 2009-05-20 2010-11-25 Heart Metabolics Limited Treatment of heart failure with normal ejection fraction
GB0908193D0 (en) 2009-05-13 2009-06-24 Albright Patents Treatment of disease state

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457017B2 (en) 2007-11-23 2016-10-04 Heart Metabolics Limited Treatment of heart failure
US9468634B2 (en) 2007-11-23 2016-10-18 Heart Metabolics Limited Treatment of heart failure

Also Published As

Publication number Publication date
PT1732551E (en) 2011-02-15
JP5087389B2 (en) 2012-12-05
EP1732551B1 (en) 2010-11-10
JP2007528378A (en) 2007-10-11
MXPA06010397A (en) 2007-04-23
DE602004030048D1 (en) 2010-12-23
EP1732551A1 (en) 2006-12-20
GB0405381D0 (en) 2004-04-21
ATE487480T1 (en) 2010-11-15
US8470806B2 (en) 2013-06-25
CN1950084A (en) 2007-04-18
DK1732551T3 (en) 2011-02-28
US8697677B2 (en) 2014-04-15
US20070275997A1 (en) 2007-11-29
WO2005087233A1 (en) 2005-09-22
US20120101128A1 (en) 2012-04-26
PL1732551T3 (en) 2011-05-31
US20130224118A1 (en) 2013-08-29
ES2358514T3 (en) 2011-05-11

Similar Documents

Publication Publication Date Title
US8697677B2 (en) Perhexiline for treating chronic heart failure
Tsang et al. Effects of quinapril on left atrial structural remodeling and arterial stiffness
US8697728B2 (en) Perhexiline for use in the treatment of hypertrophic cardiomyopathy (HCM)
US20110166220A1 (en) Dronedarone for the prevention of permanent atrial fibrillation
US9457017B2 (en) Treatment of heart failure
US20110230552A1 (en) Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack
TW202140058A (en) Therapeutic uses of tirzepatide
KR100623166B1 (en) Use of cortisol antagonists in the treatment for heart failure
Morisco et al. Lisinopril in the treatment of congestive heart failure in elderly patients: comparison versus captopril
JP2005531492A (en) Method for reducing type II diabetes in high-risk patients
EP4477224A1 (en) Pharmaceutical composition comprising allopurinol, febuxostat, or a pharmaceutically acceptable salt thereof for preventing or treating cardiovascular disease of subject having high blood uric acid level
Wang et al. Polypharmacology in Clinical Applications: Cardiovascular Polypharmacology
Gaddam et al. Diastolic dysfunction and heart failure with preserved ejection fraction: rationale for RAAS antagonist/CCB combination therapy
Yoshitomi et al. Significance of pulsatility of brachial artery pressure for blood pressure control
O'Donovan Amiodarone as a class III antiarrhythmic drug
Le et al. Heart failure (stages A, B and C)
Al Azza et al. Heart Failure (Stages A, B and C)
Kitzman et al. EPIDEMIOLOGY AND RISK FACTORS
Fisher et al. Diabetes and the Heart
EP2387996A1 (en) Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients with permanent atrial fibrillation
HK1158984A (en) Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack
EP2431033A1 (en) Dronedarone for preventing cardiovascular hospitalization or mortality in patients with lone atrial fibrillation

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION